MedPath

Effects of Two Anti-HIV Drug Regimens on Quality of Life and Health Care Use Among SMART Study Participants

Completed
Conditions
HIV Infections
Interventions
Drug: Antiretroviral Regimens
Registration Number
NCT00385632
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

The purpose of this study is to compare the effects of two different anti-HIV drug regimens on quality of life and health care utilization among SMART study participants.

Detailed Description

Advances in antiretroviral therapy (ART) have dramatically reduced mortality and morbidity rates for HIV infected people. However, HIV infection is a costly disease to treat. With improvement in survival, quality of life and the long-term cost of HIV treatment have become increasingly important to the majority of individuals infected with HIV. Different HIV treatment regimens may lead to variations in quality of life and health care costs over the course of treatment. In the SMART study, participants were randomly assigned to one of two treatment groups:

* Group 1 participants followed a drug conservation (DC) regimen in which ART was stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count was at least 350 cells/mm3, and then followed by episodic ART based on CD4 cell count.

* Group 2 participants followed a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count.

The purpose of this study is to compare how the DC and VS regimens affect quality of life, symptom severity, health care utilization, and resulting costs among SMART study participants.

At baseline, participants will complete questionnaires regarding quality of life, symptoms, health care utilization, current insurance, and socioeconomic status. Body appearance and signs of HIV disease progression will also be assessed at this time. Follow-up evaluations on quality of life and symptoms will be repeated at Months 4, 8, and 12 and annually thereafter. Follow-up evaluations of all other baseline measures will occur once a year.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1224
Inclusion Criteria
  • Coenrollment in the SMART study
  • Parent or guardian willing to provide informed consent, if applicable
Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
1Antiretroviral RegimensParticipants following a drug conservation (DC) regimen in which ART was stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count was at least 350 cells/mm3, and then followed by episodic ART based on CD4 cell count
2Antiretroviral RegimensParticipants following a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count
Primary Outcome Measures
NameTimeMethod
Quality of life as assessed by self-administered questionnaires, a symptom severity survey, and an assessment of body appearanceThroughout study
Self-reported healthcare utilizationThroughout study
Recorded medications used by participantsThroughout study
Cost of treating HIV/AIDSThroughout study
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (67)

UCSF, Fresno, School of Medicine, Dept. of Internal Medicine CRS

🇺🇸

Fresno, California, United States

Dr. M. Estes Med. Practice CRS

🇺🇸

Mill Valley, California, United States

Dr. Robert Scott Med. Practice CRS

🇺🇸

Oakland, California, United States

East Bay AIDS Ctr. CRS

🇺🇸

Oakland, California, United States

Dr. Shawn Hassler Med. Practice CRS

🇺🇸

San Francisco, California, United States

Positive Health Program Clinic (San Francisco Gen. Hosp.) CRS

🇺🇸

San Francisco, California, United States

Dr. Virginia Cafaro Med. Practice CRS

🇺🇸

San Francisco, California, United States

Dr. William Owen Med. Practice CRS

🇺🇸

San Francisco, California, United States

Castro-Mission Health Ctr. CRS

🇺🇸

San Francisco, California, United States

San Francisco VAMC, Infectious Diseases Clinic CRS

🇺🇸

San Francisco, California, United States

Scroll for more (57 remaining)
UCSF, Fresno, School of Medicine, Dept. of Internal Medicine CRS
🇺🇸Fresno, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.